BioLargo, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLGO research report →
Price Chart
About the company
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections.
- CEO
- Dennis Calvert
- IPO
- 2007
- Employees
- 45
- HQ
- Westminster, CA, US
Get TickerSpark's AI analysis on BLGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.43M
- P/E
- -2.11
- PEG
- 0.12
- P/S
- 5.76
- P/B
- -4.38
- EV/EBITDA
- -2.01
- Div Yield
- 0.00%
- Gross Margin
- 40.45%
- Op Margin
- -373.11%
- Net Margin
- -260.70%
- ROE
- 3302.10%
- ROIC
- -496.63%
Latest fiscal year · YoY change
- Revenue
- $7.76M-56.3%
- Gross Profit
- $3.41M-56.6%
- Op Income
- $-14,841,000
- Net Income
- $-11,780,000-390.4%
- EPS
- $-0.04-374.1%
- OCF Growth
- -158.8%
- FCF Growth
- -87.9%
- 52W High
- $0.20
- 52W Low
- $0.06
- 50D MA
- $0.08
- 200D MA
- $0.12
- Beta
- -0.12
- RSI (14)
- 49
- Avg Volume
- 409.08K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioLargo framed the quarter as a difficult but pivotal transition period, with legacy revenue disruptions weighing on results while multiple subsidiaries moved closer to commercialization and potential value realization.· September 10, 2026
- Pooph-related revenue loss and a roughly $4 million write-down were major drags on performance and sentiment.
- Management said core operations improved quarter to quarter, with engineering revenue growth and stronger third-party customer sales.
- Clyra advanced with three active distributors and a fourth major national partner nearing launch, though timing and setup remain uncertain.
- The PFAS business now has a commercial reference site, an Aquatech alliance, and several pilots, while a new Tu Nipi venture targets oil-sands and other water opportunities.
- BioLargo CPG is being rebuilt in-house after the Pooph fallout, with management targeting a relaunch in October and suggesting meaningful ramp potential over 12-18 months.
Management did not provide a full quarterly income statement on the call, but it reiterated that the company’s market cap had declined almost 70% over the prior year and that the Pooph exit caused a meaningful revenue loss plus a close to $4 million write-down. Charles Dargan said the parent company needs about $250,000 per month to run current operations, and that 86% of new capital raised came from outside the parent company. He also said BioLargo ended the period with over $2 million in cash, while about $650,000 of capital came in over roughly four months including subsequent events. On the operating side, he said the engineering group’s revenue increased quarter to quarter and the core business improved. For water-related activities, management said total revenues since inception were about $1.7 million. Forward-looking commentary included an expected October launch for consumer products, a near-term launch process for Clyra’s large partner, a prior 2027 start reference for that channel, and a Cellinity battery model that could involve about $250 million of CapEx and a factory cost of about $170 million each.
Dennis Calvert’s message was that BioLargo is a portfolio-building company that creates value by finding unique technologies, proving them up, and then scaling through partners rather than trying to self-fund everything. He was emphatic that the company’s strategy has been durable despite long timelines, and he repeatedly argued that recent setbacks are temporary compared with the underlying asset value. His tone was defiant and optimistic, especially around Clyra, PFAS, Tu Nipi, and the consumer products relaunch, which he described as potentially value-changing if execution and capital follow.
Charles Dargan focused on the balance sheet and the burden of consolidation. He said the parent company’s run-rate overhead is about $250,000 per month, that the company raised about $650,000 over roughly four months, and that over $2 million in cash remained on the balance sheet. He also pointed out that the company’s structure means Clyra’s capital needs and losses are consolidated even though third-party investors are funding much of that activity, and he emphasized that the engineering business is growing revenue quarter to quarter and is basically self-sufficient aside from R&D.
Analysts and investors focused on why the stock trades far below the implied value of the subsidiaries, how quickly Pooph-like revenue could be replaced, and what the monthly corporate burn really is. Management answered that the valuation gap reflects long development timelines, heavy investment to de-risk assets, and the Pooph disruption, including the lost revenue and close to $4 million write-down. On replacement revenue, management said consumer products could target roughly half of Pooph’s historical scale, potentially in the $15-plus million range over 12 to 18 months, but that Clyra, PFAS, and Tu Nipi also provide other paths to offset the gap. On the large Clyra partner, management said some distribution is effectively plug-and-play, but major systems will still negotiate pricing and need roughly 3 to 6 months of setup before acceleration.
The bull case from this call is that BioLargo is sitting on several assets that management believes are much closer to monetization than the market implies. Clyra has FDA-cleared products, multiple distributors, and a major partner nearing launch; PFAS has a commercial site, pilots, and an Aquatech alliance; and the consumer products relaunch is being built around a proven playbook with ownership of the brand this time. Management also stressed low corporate overhead and substantial outside capital support at the subsidiary level.
The main risks are execution timing, capital intensity, and prior business disruption. Management acknowledged that Pooph’s collapse, the associated lost revenue, and the close to $4 million write-down hit the business hard, while Clyra still needs more money and a large-partner rollout may take months even after paperwork is complete. The Cellinity battery opportunity also remains highly speculative until financed, and management repeatedly said several of the value drivers depend on partnerships, regulatory progress, and market adoption that are not yet fully in hand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.9%
- Shares Outstanding
- 334.66M
- Float Shares
- 290.93M
of shares held by institutions
1 13F filers
Buy/sell ratio 10.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First American Trust, Fsb | 117.84K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | CODE KENNETH REAY | other | 566,261 |
| Sep 30, 26 | CODE KENNETH REAY | other | 2,000,000 |
| Sep 30, 26 | CALVERT DENNIS P | other | 2,000,000 |
| Sep 30, 26 | CALVERT DENNIS P | other | 931,886 |
| Sep 30, 26 | Marshall Dennis E | other | 234,375 |
| Sep 30, 26 | Marshall Dennis E | other | 281,248 |
| Sep 30, 26 | STROMMEN JACK B. | other | 187,500 |
| Sep 30, 26 | Bray Christina Elaine | other | 234,375 |
| Sep 30, 26 | Park Linda | other | 234,375 |
| Jul 7, 26 | CODE KENNETH REAY | other | 532,567 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLGO coverage
Recent articles, reports, and earnings notes.
No research on BLGO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLGO report →BioLargo Subsidiary Clyra Medical to Exhibit at SAWC Fall 2026 in Las Vegas
accessnewswire.com · Oct 13
BioLargo, Inc. (BLGO) Q2 2026 Earnings Call Transcript
seekingalpha.com · Sep 11
BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More
accessnewswire.com · Sep 10
BioLargo Townhall and Q2 2026 Earnings Results Webcast and Conference Call on Thursday, September 10th, 2026 - 4:00 PM Eastern Time
accessnewswire.com · Sep 9
BioLargo's Subsidiary Clyra Medical Adds Third Distribution Channel Accelerating Commercial Rollout of ViaClyr Wound Irrigation Solution
accessnewswire.com · Sep 3
BioLargo, Inc. to Present at the Inaugural Nasdaq / LD Micro Summit on September 9, 2026
accessnewswire.com · Sep 1
Critical Review: BioLargo (NASDAQ:BLGO) and Akzo Nobel (OTCMKTS:AKZOD)
defenseworld.net · Aug 28
BioLargo to Participate in Gabelli Funds' 4th Annual PFAS Symposium in New York
accessnewswire.com · Aug 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.